Retina
Retina
5 years ago

ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ERA

DeCroos, Francis C., Ambresin, Aude, Spirn, Marc, Tsui, Irena, Yung, Madeline, Tam, Emily K., Lehmann-Clarke, Lydia, Golchet, Pamela
Purpose: Anti–vascular endothelial growth factor therapy has improved the prognosis for patients with central retinal vein occlusion (CRVO). However, most studies published to date exclude ischemic CRVO. The purpose of this study was to describe the outcome in eyes with ischemic CRVO treated with anti–vascular endothelial growth factor therapy. Methods: Thirty-seven patients with ischemic CRVO from 3 centers were followed for at least 6 months. Data on patient demographic, vision status, and anti–vascular endothelial growth factor treatments were collected. Results: Average number of injections during the study period was 5. Younger age was associated with improved vision (P = 0.006). Patients with improved visual outcomes tended to have macular edema as the primary indication for treatment, whereas patients with worse outcomes tended to have neovascularization as the primary indication for treatment. Conclusion: This study highlights significant variability in the use of anti–vascular endothelial growth factor therapy for ischemic CRVO and underscores that eyes with neovascularization tend to have worse visual outcomes.

Publisher URL: https://journals.lww.com/retinajournal/Fulltext/2018/02000/ISCHEMIC_CENTRAL_RETINAL_VEIN_OCCLUSION_IN_THE.10.aspx

DOI: 10.1097/IAE.0000000000001546

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.